Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

14.02 -0.22 (-1.58%)
Streaming Delayed Price Updated: 10:17 AM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Design Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Monday's pre-market session: top gainers and losers ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Preview For Design Therapeutics ↗
 
Via Benzinga
News headline image
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains ↗
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
News headline image
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024 ↗
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying ↗
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023 ↗
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 19, 2024 ↗
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. 
Via Benzinga
News headline image
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Topics Stocks
News headline image
Market Sentiment Teeters As US Indices, Including S&P 500, Break Key Supports: Next Levels To Watch ↗
All three leading U.S. stock indices — the S&P 500, Nasdaq 100, and Russell 2000 — have simultaneously breached a crucial technical support level this week. 
Via Benzinga
Topics Stocks
News headline image
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments ↗
RBC Capital Market downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Sector Perform with a price target of $7,  
Via Benzinga
News headline image
Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded down 0.82% to 35,017.95 while the NASDAQ fell 0.77% to 13,682.54. The... 
Via Benzinga
Topics Stocks
News headline image
Why Shares of Design Therapeutics Are Plummeting on Tuesday ↗
The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.